The Phenomix CEO discusses recent data that suggests that patients may not be prepared for the side effects and unexpected costs of GLP-1s.
Mark Bagnall
Advertisement
Mark Bagnall is CEO of Phenomix.
Articles by Mark Bagnall
Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.
Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.
GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.
Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Top Drugs at Risk of Supply Shortages: Report
2
FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression
3
Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free
4
Amazon One Medical Launches GLP-1 Management Program
5